Abstract 500P
Background
With the advances of next-generation sequencing (NGS), compound EGFR mutations were more frequently observed. Prior studies reported that patients with compound EGFR mutations showed poor clinical outcome. However, molecular and clinical features of NSCLC patients harboring such mutations were poorly investigated.
Methods
A total of 1091 primary NSCLC patients were enrolled. Variants of EGFR and other driver genes were analyzed by NGS. EGFR exon 19 deletion (19 del) and L858R mutations were defined as common sensitizing mutations; EGFR G719S/C/A mutations were defined as uncommon sensitizing mutations; other mutations were defined as rare mutations. Patients were divided as follows: common sensitizing and rare mutations (group A); uncommon sensitizing and rare mutations (group B); double rare mutations (group C).
Results
Overall, EGFR mutations were detected in 418 patients (38.3%), and 76 cases (7.0%) carried compound EGFR mutations. Frequencies of group A, B and C were 76.3%, 18.4% and 5.3%, respectively, indicating compound mutations mainly consist of sensitizing and atypical mutations. Compound mutations were more frequently observed in young patients (p = 0.017), and distributions of the three groups were different between early and adavanced stages (p = 0.032). According to types of common sensitizing mutations, rate of compound mutations harboring EGFR L858R alteration was strikingly higher than that carrying EGFR 19 del alteration (p = 0.039). Further analysis demonstrated that frequency of EGFR T790M mutation among the three groups showed significant difference (p = 0.031). Genomic data revealed TP53 mutations markedly coexisted with compound mutations compared with single mutation (p = 0.03). Moreover, relative EGFR mutant allele frequency (rMAF) of group A, calculated as MAF of EGFR sensitizing mutations / MAF of EGFR rare mutations, was higher than that of group B (p = 0.007).
Conclusions
This study comprehensively explored the population characteristics of compound EGFR mutations from a large cohort of primary NSCLC patients, which will be helpful to guide personalized therapy and promote the clinical management of this population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
H. Cheng: Honoraria (self): Beijing Acornmed Biotechnology Co., Ltd. H. Wang: Honoraria (self): Beijing Acornmed Biotechnology Co., Ltd. F. Lou: Honoraria (self): Beijing Acornmed Biotechnology Co., Ltd. S. Cao: Honoraria (self): Beijing Acornmed Biotechnology Co., Ltd. All other authors have declared no conflicts of interest.
Resources from the same session
528P - High-biologically effective dose radiotherapy may improve local control of small cell lung cancer patients with brain metastases: A propensity-matching analysis
Presenter: Qingyang Zhuang
Session: Poster display session
Resources:
Abstract
530P - Prognostic value of C-reactive protein, albumin and C-reactive protein to albumin ratio in small cell lung cancer: A meta-analysis
Presenter: Carla Emille Barbon
Session: Poster display session
Resources:
Abstract
531TiP - CANOPY-A: A phase III, placebo-controlled study of canakinumab as adjuvant therapy in patients (pts) with surgically resected NSCLC
Presenter: Byoung Chul Cho
Session: Poster display session
Resources:
Abstract
532TiP - CANOPY-1: A phase III, placebo-controlled study of pembrolizumab (PEM) plus platinum-based doublet chemotherapy (Ctx) with/without canakinumab in untreated patients (pts) with stage IIIB/IIIC-IV NSCLC
Presenter: Daniel Shao Weng Tan
Session: Poster display session
Resources:
Abstract
533TiP - CANOPY-2: A phase III, placebo-controlled study of canakinumab with or without docetaxel in patients (pts) with NSCLC previously treated with PD-(L)1 inhibitors and platinum-based chemotherapy (Ctx)
Presenter: Darren Lim
Session: Poster display session
Resources:
Abstract
534TiP - A randomized phase III study of carboplatin plus nab-paclitaxel with or without nintedanib for NSCLC with IPF (J-SONIC)
Presenter: Kohei Otsubo
Session: Poster display session
Resources:
Abstract
535TiP - Phase II study of atezolizumab for pretreated advanced / recurrent non-small cell lung cancer with idiopathic interstitial pneumonia (TORG1936 / AMBITIOUS study)
Presenter: Satoshi Ikeda
Session: Poster display session
Resources:
Abstract
536TiP - INSIGHT 2: Tepotinib plus osimertinib in patients with EGFR-mutant NSCLC having acquired resistance to EGFR TKIs due to MET-amplification: A phase II trial in progress study
Presenter: James C-H Yang
Session: Poster display session
Resources:
Abstract
YO8 - Carcinosarcoma of the Breast in a Filipino Female: A Case Report
Presenter: Ma. Angelle Lalaine Dantes
Session: Poster display session
Resources:
Abstract
YO9 - Small Malignant Phyllodes Tumor of the Breast with Metastases to the Lung and Bone
Presenter: Gusti Harti
Session: Poster display session
Resources:
Abstract